|
Display additional annotations [+]
|
| |
Fig. 10. paraxis depletion disrupts the expression of myogenic markers. Embryos were unilaterally injected with 1 ng of DNparaxis-GR mRNA (A–D), 40 ng of paraxisMO (E–G, I–K, and Q–S), 40 ng of CtrMO (H, M and T), or a blend of 40 ng of paraxisMO and 0.2 ng of Rparaxis-GFP mRNA (N and O), and subsequently processed for in situ hybridization assay (A–O) or immunohistochemical (Q–T). A–C,E–G: The loss of function of paraxis reduces the expression of the MyoD myogenic marker in PSM and somites (indicated by arrow). D: Control embryo injected with the DNparaxis- GR mRNA and cultured in the absence of dexamethasone. H: CtrMO morpholino does not affect the expression of MyoD myogenic marker. I,J: The loss of function of paraxis reduces the expression of Myf-5 myogenic marker. K: Transverse section at the dotted line of J. M: CtrMO does not affect the expression of Myf-5. N,O: The downregulation of MyoD and Myf-5 expression by paraxisMO is rescued by coinjection with Rparaxis-GR construct. P: Numerical summary illustrating the penetrance of effect of paraxis knockdown and the rescue of myogenic markers expression. Q: The loss of function of paraxis reduces the expression of the 12/101 myogenic marker. R: Control side of Q. S: Transverse section of Q. T: Control embryo. Insets A and E, transverse section at the dotted line. |
|
Display additional annotations [+]
|
| |
Fig. 12. Gain of function of paraxis increases myogenic markers expression. Embryos were unilaterally injected with 1 ng of paraxis-GR mRNA and processed for in situ hybridization assay. A–C,E–F: The gain of function of paraxis increases the expression of myogenic markers Myf-5 and MyoD (indicated by arrow). B: Transverse section at level of the dotted line. D: Control side of C. G: Control embryo cultured in the absence of dexamethasone. H: Numerical summary illustrating penetrance of gain of function of paraxis in myogenic markers expression. |
